* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Enzymes - Michael P. Ready
Nicotinamide adenine dinucleotide wikipedia , lookup
Citric acid cycle wikipedia , lookup
Basal metabolic rate wikipedia , lookup
Ultrasensitivity wikipedia , lookup
Deoxyribozyme wikipedia , lookup
Photosynthetic reaction centre wikipedia , lookup
Biochemistry wikipedia , lookup
Oxidative phosphorylation wikipedia , lookup
Metalloprotein wikipedia , lookup
Evolution of metal ions in biological systems wikipedia , lookup
Amino acid synthesis wikipedia , lookup
NADH:ubiquinone oxidoreductase (H+-translocating) wikipedia , lookup
Biosynthesis wikipedia , lookup
Catalytic triad wikipedia , lookup
Discovery and development of neuraminidase inhibitors wikipedia , lookup
Enzymes CH339K Transition State • On the way from reactants to products, the reaction goes through a high-energy intermediate structure • Amount of energy to reach transition state controls rate • Picture is from an O-Chem text – sorry - ugggghhhhhhhh Reaction Pathways DGo’ is the difference in Free Energy between reactants and products DGo’determines Keq Rate depends on EA or DG‡ how much energy is required to reach transition state. What are enzymes? • There are two basic ways to increase the rate of a reaction – Increase the energy of the reactants (heat it up) – Lower the activation energy (catalysis) • Enzymes are protein catalysts. • Virtually every biochemical reaction is mediated by an enzyme. For the Visual Thinkers: Two Options Raise the temperature of the reactants Use a catalyst Which is: a) Faster? b) Less likely to result in being eaten? Activation Energy (you knew it would get to math) EA G DG0 X X' Y Reaction Coordinate • Let’s look at a first-order reaction where substance X is converted to substance Y, going through the transition state X’: X ⇌ X’ ⇌ Y • The rate can be expressed as a rate constant k times the concentration of the reactant X: [1] v = k * [X] Activation Energy (cont.) But if we think about it, Y is actually produced from the transition state, so the reaction velocity should really be governed by the concentration of transition state: [2] v = k’ * [X’] Now let’s assume we have a situation where X’ is far more likely to fall back to X than to proceed to form the product Y. Then X’ will essentially be in equilibrium with X, and the equilibrium will be governed by the same thermodynamic rules we have seen before: [3] [4] or [5] X ⇌ X’ (forget Y for a second) [X '] E A / RT Keq e [X ] [X '] e E A / RT [X ] Activation Energy (cont.) • [6] • [7] so combining [2] and [5] v k '*e E A / RT [X ] Lowering the activation energy from EA1 to EA2 thus changes the rate by a factor of v2 e v1 E1A E2A RT i.e. lowering EA from 20 kJ/mol to 8 kJ/mol increases the rate by over 100x at 37o C!!! Enzymes tend to be really good catalysts 21,000,000-fold rate increase How do enzymes work? • Enzymes bind substrates in an active site, where the reaction takes place • Lock and key vs. induced fit (distortion of both enzyme and substrate plays a role in catalysis) Active site • The active site frequently forms a cleft in the molecule • Substrate binding typically includes van der Waals contacts, Hbonds, and salt links, but can include covalent links. Mechanisms • Increase effective concentrations • Orient the substrates • Stabilize the transition state – The energy of binding can subsidize conformational strain in the substrate – Acids and bases can participate in catalysis • Covalent or redox participation by the enzyme • Use of enzyme cofactors Acid-base catalysis: Triose Phosphate Isomerase • Triose phosphate isomerase interconverts the two three-carbon sugars formed by the action of aldolase on fructose-1,6-bisphosphate in the glycolytic pathway Acid-base catalysis: Triose Phosphate Isomerase • Glu165 acts as a base, extracting a proton from the substrate • His95 acts as an acid, donating a proton. DHAP G3P Acid-Base + Conformational Change Lysozyme • In 1922, Alexander Fleming plated bacterial cultures along with samples of his own snot. • Bacteria near his nasal mucus dissolved away. • The active ingredient, lysozyme, cleaves bacterial cell wall polysaccharides. • There is an extended substrate binding cleft that bonds a stretch of 6 sugars. • Lysozyme cleaves its substrate between the fourth and fifth residues in a hexasaccharide Repeating Structure of Cell Wall Lysozyme cleaves here Acid-Base + Conformational Change Lysozyme (from egg white, not snot) Active Site Cleft Lysozyme with 3 NAG in the active site Lysozyme with hexose in the active site Acid-Base + Conformational Change Lysozyme • Glu35 acts as an acid (has abnormally high pKa). • Asp52 stabilizes the charge on the oxycarbonium transition state. • Binding of 6 sugars subsidizes the torsion of the target sugar bond into a half-chair conformation. • This mimics the conformation of the intermediate, decreasing DG‡ for reaching the transition state. Transition State Analogs Raising Monoclonal Antibodies Transition State Analogs • One can create catalytic antibodies by rearing antibodies against transition state analogs Hydrolysis of Aryl Carbonates using p-nitrophenyl-4carboxybutanephosphonate as antigen – rate acceleration > 104. Patten, P.A. et al, (1996) Science 271: 1086-1091. Covalent Participation - Chymotrypsin • Three key catalytic side chains - Far apart in sequence but adjacent in active site – Ser195 – His57 – Asp102 Covalent Participation - Chymotrypsin • Chymotrypsin is a serine protease. • Serine, Histidine, and Aspartic Acid form a charge relay system. Subtilisin • • • • From Bacillus subtilis Same catalytic mechanism Totally different protein; no evolutionary connection. Triad: Ser221, His64, Asp32 Inorganic Cofactors Coenzymes Example of use of a cofactor • Histidine Decarboxylase Redox cofactors Flavin Adenine Dinucleotide (FAD) Nicotinamide Adenine Dinucleotide (NAD+) Nicotinamide Adenine Dinucleotide Phosphate (NADP+) Example of a redox cofactor Glycolate Oxidase Uses Flavin Mononucleotide (FMN) FMN (oxidized) FMN (reduced) + H H H3C N H3C O N HO N H3C N H O CO2 Glycolic acid (reduced) O N NH N H H3C NH H - Glyoxylic acid (oxidized) O O H + H+ CO2 - STOP HERE ENOUGH IS ENOUGH Enzyme Kinetics • Let's make a simple model of an enzyme-catalyzed reaction that converts one molecule of substrate (S) to one molecule of product: • Let's also make a few assumptions: – The reaction has just started, so [P] = 0 and k4 can be ignored. – [S] >>> [E], so substrate is in no way limiting. – As a result of (2), [S] isn't going to change appreciably during our observation of the reaction and we can assume [ES] is approximately constant. Enzyme Kinetics • • We will define [Etotal] as the total concentration of the enzyme. [Etotal] = [E] + [ES] We will define v as the reaction velocity for formation of product v = k3[ES] Enzyme Kinetics • Since [ES] is approximately constant, its rate of formation is equal to its rate of destruction: k1 [E][S] = (k2 + k3)[ES] [E][S] = ((k2 + k3)/k1)[ES] • Let's give a name to the combined constants. Let's call it Km (for the Michaelis constant): [E][S] = Km[ES] ([Etotal] - [ES])[S] = Km[ES] (since [Etotal] = [E] + [ES]) [Etotal][S] - [ES][S] = Km[ES] Enzyme Kinetics [Etotal][S] - [ES][S] = Km[ES] • Rearranging: Km[ES] + [ ES][S] = [Etotal][S] [ES] = [Etotal][S] / (Km + [S]) • Remember v = k3[ ES], so v = k3[Etotal][S] / (Km + [S]) • The maximum velocity for the rxn is when every enzyme molecule is part of an ES complex: Vmax = k3[Etotal] Enzyme Kinetics • The maximum velocity for the rxn is when every enzyme molecule is part of an ES complex: Vmax = k3[Etotal] and v = k3[Etotal][S] / (Km + [S]) There’s that blue arrow again! • Simplifying the above: v = Vmax[S] / (Km + [S]) – This is the Michaelis - Menten equation, which does a pretty good job of describing the overall kinetics of many enzyme catalyzed reactions. You’ve seen this before (1) Vmax S v K m S (2) v S Vmax K m S (3) pO 2 p50 pO 2 kcat • • Vmax will change with changing enzyme concentration. It would be nice if we could define a term equivalent to Vmax which was independent of enzyme concentration. In addition, there are many enzyme catalyzed reactions that have several intermediate steps in the pathway from reactants to products. For example: where EI1, EI2, EI3 are complexes between the enzyme and successive intermediates. • What we can normally measure is not the set of individual reaction rates but rather an overall 'k3apparent' or kcat. • kcat is enzyme-adjusted measured Vmax; that is, kcat = Vmax/[Etotal] (units of sec-1) Km • Km is th Substrate concentration at which the reaction is occurring at one-half its maximal rate. It is thus a measure of how much substrate is required for reasonable enzyme activity. Km is often looked on as a dissociation constant for the Enzyme -Substrate complex. Since Km = (k2 + k3)/k1, • this will only be true when k3 << k2! This is frequently the case, but not necessarily! kcat/Km • At low substrate concentrations, the Michaelismenten equation reduces to v = (kcat/Km)*[Etotal][S] • i.e. at low [S], [E] ~ [Etotal] and Km + [S] ~ Km. • kcat/Km is thus a rate constant and as such is a measure of catalytic efficiency. • Theoretical maximum for the reaction rate is in the range of 108 - 109 M-1sec-1. • Many enzymes approach this limit and are thus said to have achieved catalytic perfection. Sample Kinetic Parameters for Enzymes Measuring Km and Vmax (if you only have a pencil and a ruler) Rearrange Michaelis-Menten Equation: • Lineweaver-Burke 1 Km 1 1 v vmax [ S ] vmax • Eadie-Hofstee v vmax v Km [S ] Lineweaver-Burke Eadie-Hofstee Control by Inhibition • • • • Inhibitors alter enzyme activity (Km and kcat) Often used to control enzyme activity Often used as toxins Two basic flavors – Irreversible – Reversible • Which are pretty much like they sound Irreversible Inhibition at the NM Junction Nerve Gases Sarin Tabun Soman VX Symptoms: Contraction of pupils, profuse salivation, convulsions, involuntary urination and defecation and eventual death by asphyxiation as control is lost over respiratory muscles. Nerve Gases - Properties Toxicity of Nerve Agents Agent LD50 LCt50 Tabun (GA) 1000 mg 400 mg/min-m3 Sarin (GB) 1700 mg 100 mg/min-m3 Soman (GD) 50 mg 70 mg/min-m3 VX 10 mg 50 mg/min-m3 Action of Nerve Agents Nerve Gas Antidotes Atropine sulfate from Atropa belladonna (left) competes with acetylcholine for the receptor binding site Blocks ACH and offsets the effects of the nerve agent How do I take atropine? Instructions for use is outlined in STP21-1-SMCT, Soldier’s Manual of Common Tasks- Skill Level 1. You may self-administer the injection as follows: • Hold the injector in your hand forming a fist around the injector without covering or holding the needle end. • Place the end of the injector against your outer (lateral) thigh muscle anywhere from about a hand’s width above the knee to a hand’s width below the hip joint. Very thin soldiers should give the injection in the upper outer part of the buttocks. • Push the injector into the muscle with firm, even pressure until it functions. • Hold the injector in place for 10 seconds to allow the 2-PAM CL to be administered. • After you have given yourself the first set of injections, you most likely will not need an additional antidote if you can walk and know who and where you are. If needed, the second and third sets of injections will most likely be given by a buddy or by medical personnel. From Atropine Nerve Agent Autoinjector – What You Need to Know, U.S. Army Center for Health Promotion and Preventive Medicine (USACHPPM) Pralidoxime Hydrochloride Usually given along with atropine Reversibly binds to the enzyme acetylcholinesterase, competing with organophosphate binding. Doesn’t inhibit acetylcholinesterase – reactivator. 2-PAM Action Reversible Inhibition Competitive Inhibition • Inhibitor binds to active site • Competes with normal substrate • Effect of inhibitor can be overcome by increasing [S] • In presence of inhibitor: – Vmax unchanged – Km increases K app m [I ] K m 1 KI Competitive Lineweaver-Burke Competitive - Example • • • • Ethylene Glycol (Antifreeze) is a poison. It is converted into Oxalic Acid. Oxalic acid binds calcium and forms crystals in the kidney and brain The old treatment for antifreeze poisoning was legal drunkenness. Ethanol acts as a competitive inhibitor for ethylene glycol on alcohol dehydrogenase. Substrate* Km Ethylene Glycol 30 mM Methanol 7 mM Ethanol 0.45 mM * Data from Goldfrank, L.R. et al, Goldfrank’s Toxologic Emergencies, 1998, New York Diagnosis (in critters) • Presence of calcium oxalate crystals in the urine. Newer Treatment (for all you medical types) Fomepizole • Specifically indicated for use in ethylene glycol and methanol poisoning • Also a competitive inhibitor of alcohol dehydrogenase Competitive - Another Example • The ricin substrate is an adenosine residue in the large ribosomal RNA Another example (cont.) • Pteroic Acid acts as a (not terribly good) competitive inhibitor of ricin, binding to the same residues as adenosine Pteroic Acid Pteroic Acid Inhibition Substrate Km Intact Eukaryotic Ribosome 2.6 mM 28S rRNA 5.8 mM 23S (E. coli) rRNA 3.3 mM Pteroic Acid 600 mM Noncompetitive Inhibition • Inhibitor binds at separate location from active site • Inhibited ES complex does not proceed to products • Effect of inhibitor cannot be overcome by increasing [S] • In presence of inhibitor: – Vmax decreases – Km unchanged • Not many purely noncompetitive inhibitors app Vmax Vmax 1 [KI I] Noncompetitive Lineweaver-Burk Noncompetitive - Example • Browning of fruit is caused by a reaction between catechols and oxygen, catalyzed by catechol oxidase, resulting in benzoquinone. • Catechol oxidase requires Cu+2 as a cofactor. • Phenylthiourea binds to Cu and is a noncompetitive inhibitor of the enzyme Uncompetitive Inhibition • Inhibitor binds only to ES complex • Inhibited ES complex does not proceed to products • Effect of inhibitor potentiated by increasing [S] • In presence of inhibitor: – Vmax decreases – Km decreases • Uncompetitive inhibitors are relatively rare, typically toxic K app m Km [I ] 1 KI app max V Vmax [I ] 1 KI Uncompetitive - Example • • • • The enzyme 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS) catalyzes the reaction of shikimate-3-phosphate (S3P) and phosphoenolpyruvate to form 5-enolpyruvyl-shikimate-3-phosphate (ESP). ESP is an essential precursor in plants for the aromatic amino acids. Glyphosate binds to the EPSPS • S3P complex and inhibits enzyme activity. As [S3P] increases, more of the complex is formed and the effect of the inhibitor increases. Glyphosate Glyphosate = In addition to glyphosate usage, the sale of glyphosate-resistant crop plants has also gone through the roof. $$$$$$$$$!!! Allostery allostery • A phenomenon whereby the conformation of an enzyme or other protein is altered by combination, at a site other than the substrate-binding site, with a small molecule, referred to as an effector, which results in either increased or decreased activity by the enzyme. • E.g. 2,3-bisphosphoglycerate is an allosteric inhibitor of hemoglobin Aspartate Transcarbamoylase • Important enzyme in the biosynthesis of pyrimidine nucleotides (i.e. need it to make DNA) • Catalyzes addition of carbamoyl phosphate to aspartate to make N-carbamoyl aspartate ( Uracil, a Pyrimidine ) ATCase - Structure • 12 subunits totalling ~300 kDal • two catalytic components each made up of three identical subunits (34 kDal each) • three regulatory components each comprising two subunits (17 kDal each) ATCase • Active sites are at the intersections of C subunits • Allosteric sites are on R subunits • Latter bind UTP/CTP (inhibitor) and ATP (activator} • T to R transition opens molecule, making active sites accessible • ATP binds / stabilizes R • CTP/UTP bind / stabilize T ATCase – Binding Sites ATCase – Activation and Inhibition ATCase – An Interesting Inhibitor PALA – Another view PALA Activation/Inhibition The effect of PALA on the activity ofP. aeruginosa ATCase. The ATCase was assayed using 5 mm carbamoyl phosphate and either 8 (●) or 12 mm (○) aspartate and a variable concentration of the bisubstrate inhibitor, PALA, in the presence of 2 μm ATP. Vickery, J.F., Herve, G., and Evans, D. R. (2002) J. Biol. Chem. 277: 24490-24498.